转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

IJC：丁健等mTOR激酶抑制剂联合用药研究获进展

2014-05-06 上海药物研究所 上海药物研究所

mTOR激酶
关注

mTOR信号通路是调控细胞生长与增殖的一个关键通路，并在多数人恶性肿瘤中高度激活，成为抗肿瘤药物研究和开发的热点。新一代mTOR激酶抑制剂由于它们能同时抑制mTORC1和mTORC2，在临床前研究中具有优于雷帕霉素的抗肿瘤活性。 中国科学院上海药物研究所丁健课题组建立了mTOR激酶抑制剂的发现和研究平台，在研究新mTOR抑制剂X-387的抗肿瘤作用机制（Biochem Pharmacol 201

mTOR信号通路是调控细胞生长与增殖的一个关键通路，并在多数人恶性肿瘤中高度激活，成为抗肿瘤药物研究和开发的热点。新一代mTOR激酶抑制剂由于它们能同时抑制mTORC1和mTORC2，在临床前研究中具有优于雷帕霉素的抗肿瘤活性。

中国科学院上海药物研究所丁健课题组建立了mTOR激酶抑制剂的发现和研究平台，在研究新mTOR抑制剂X-387的抗肿瘤作用机制（Biochem Pharmacol 2012；83：1183-94）同时，发现mTOR激酶抑制剂长时间作用后AKT活性能够恢复，同时导致一系列受体酪氨酸激酶受体表达上调，成为限制mTOR激酶抑制剂抗肿瘤活性的一个重要原因，而联合用药成为克服这一缺陷的重要策略。

乳腺癌已经成为我国女性最常见的恶性肿瘤，mTOR介导的信号通路以高频率在乳腺癌中高度激活，成为乳腺癌治疗的重要靶标。丁健课题组研究人员通过研究mTOR激酶抑制剂在多种不同基因背景的乳腺癌细胞中导致存活通路反馈性激活的机制，发现GFR， HER2，HER3和IRS-1的蛋白和mRNA水平在mTOR抑制后反馈性上升。分别下调上述蛋白表达后，在不同基因背景的乳腺癌细胞中不同程度地提高了mTOR抑制剂的增殖抑制活性。由于mTOR激酶抑制剂所引起的负反馈中多种关键蛋白是Hsp90的客户蛋白，mTOR激酶抑制剂与Hsp90抑制剂联合使用协同抑制多种不同背景的乳腺癌增殖。HSP90抑制剂通过下调多种受体酪氨酸激酶蛋白水平阻碍mTOR激酶抑制剂所引起PI3K/Akt的激活。研究同时发现，mTOR抑制剂能够阻止HSP90抑制剂导致的HSP70和HSP27的反馈性上调。mTOR抑制剂和HSP90抑制剂对于目前临床上难治的三阴性乳腺癌裸小鼠移植瘤也显示出显著的协同抗肿瘤活性。

以上研究表明mTOR激酶抑制剂与HSP90抑制剂协同抑制不同基因背景尤其是三阴性乳腺癌。以联合用药的手段优化以mTOR为靶点的抗肿瘤治疗不仅进一步阐明了mTOR抑制剂的作用模式，有利于靶向mTOR的抑制剂的进一步开发，并且对于mTOR激酶抑制剂和Hsp90抑制剂在乳腺癌中的临床应用具有指导意义。

该项研究结果近日发表于International Journal of Cancer， 上海药物所研究员丁健、蒙凌华为通讯作者。项目得到了国家自然科学基金委及新药创制重大专项资助。

原始出处

Chen SM1, Guo CL, Shi JJ, Xu YC, Chen Y, Shen YY, Su Y, Ding J, Meng LH.HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.Int J Cancer. 2014 Apr 7.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851169, encodeId=20db1851169e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 08 16:55:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Feb 15 01:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801216, encodeId=4f79180121693, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Wed Feb 18 20:55:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495925, encodeId=906a149592559, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-12-08 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851169, encodeId=20db1851169e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 08 16:55:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Feb 15 01:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801216, encodeId=4f79180121693, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Wed Feb 18 20:55:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495925, encodeId=906a149592559, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2015-02-15 smartjoy

    #激酶抑制剂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851169, encodeId=20db1851169e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 08 16:55:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Feb 15 01:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801216, encodeId=4f79180121693, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Wed Feb 18 20:55:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495925, encodeId=906a149592559, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2015-02-18 axin009

    #研究获进展#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851169, encodeId=20db1851169e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 08 16:55:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Feb 15 01:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801216, encodeId=4f79180121693, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Wed Feb 18 20:55:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495925, encodeId=906a149592559, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-05-08 redcrab

    #激酶#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851169, encodeId=20db1851169e4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Dec 08 16:55:00 CST 2014, time=2014-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Feb 15 01:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801216, encodeId=4f79180121693, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Wed Feb 18 20:55:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495925, encodeId=906a149592559, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514260, encodeId=abec151426000, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Thu May 08 01:55:00 CST 2014, time=2014-05-08, status=1, ipAttribution=)]
    2014-05-08 ms4964546379600229

    #联合用药#

    0